NEA Management Company, LLC
TIMONIUM, MD · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$1.36B2026 Q3
Positions25
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.90.2%
Top Holdings
MBX
MBX Biosciences
15.5%
SGP
SpyGlass Pharma
14.1%
TRVI
Trevi Therapeutics
13.9%
CELC
Celcuity
10.0%
SVRA
Savara
9.3%
ZBIO
Zenas BioPharma
8.0%
GLUE
Monte Rosa Therapeutics
5.9%
AUPH
Aurinia Pharmaceuticals
4.7%
New / Increased
0 new · 0 increased
Reduced / Exited
2 reduced · 1 sold out
GLUE
Monte Rosa Therapeutics
5.9%
-13.0%
GOSS
Gossamer Bio
0.0%
-98.8%
KPTIEXIT
Karyopharm Therapeutics
0.4%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.